ArticleEmerging infectious diseases2009
Cost-effectiveness analysis of hospital infection control response to an epidemic respiratory virus threat.
Article in Emerging infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lessons from past pandemics: a systematic review of evidence-based, cost-effective interventions to suppress COVID-19.Systematic reviews · 2022Pooled it
- Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics.PloS one · 2012Pooled it
- The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?Cost effectiveness and resource allocation : C/E · 2023Article
- Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Review
- Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.Risk management and healthcare policy · 2020Review
- Infection control influence of Middle East respiratory syndrome coronavirus: A hospital-based analysis.American journal of infection control · 2019Article
- Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections.BMC infectious diseases · 2017Article
- Review of economic evaluations of mask and respirator use for protection against respiratory infection transmission.BMC infectious diseases · 2015Review
- A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region.PloS one · 2013Review
- Relative cost and outcomes in the intensive care unit of acute lung injury (ALI) due to pandemic influenza compared with other etiologies: a single-center study.Annals of intensive care · 2012Article
- Pandemic response lessons from influenza H1N1 2009 in Asia.Respirology (Carlton, Vic.) · 2011Review
- Risk factors for pandemic (H1N1) 2009 virus seroconversion among hospital staff, Singapore.Emerging infectious diseases · 2010Article
- Novel Coronavirus (COVID-19): Leveraging Telemedicine to Optimize Care While Minimizing Exposures and Viral Transmission.Journal of emergencies, trauma, and shockArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of influenza A pandemic (H1N1) 2009 prompted many countries in Asia, previously strongly affected by severe acute respiratory syndrome (SARS), to respond with stringent measures, particularly in preventing outbreaks in hospitals. We studied actual direct costs and cost-effectiveness of different response measures from a hospital perspective in tertiary hospitals in Singapore by simulating outbreaks of SARS, pandemic (H1N1) 2009, and 1918 Spanish influenza. Protection measures targeting only infected patients yielded lowest incremental cost/death averted of 23,000 (US dollars) for pandemic (H1N1) 2009. Enforced protection in high-risk areas (Yellow Alert) and full protection throughout the hospital (Orange Alert) averted deaths but came at an incremental cost of up to $2.5 million/death averted. SARS and Spanish influenza favored more stringent measures. High case-fatality rates, virulence, and high proportion of atypical manifestations impacted cost-effectiveness the most. A calibrated approach in accordance with viral characteristics and community risks may help refine responses to future epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.